QS
QSI.US QuantumSi Inc
- Market cap
- USD 233M
- P/E
- -
- P/B
- 1.56x
- ROE
- -56.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is QSI.US undervalued?
Graham numberThe Graham number of QuantumSi Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
QuantumSi Inc fundamental analysis
No fundamental analysis for QuantumSi Inc yet.
QuantumSi Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About QuantumSi Inc
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer's protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used…
Full company profileQuantumSi Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
QuantumSi Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 459K | 1.08M | 3.06M | 2.44M | 1.09M |
| Gross Profit | - | -894K | -1.04M | -2.58M | 488K | 1.60M | 1.15M | 427K |
| Operating Income | -36.6M | -36.7M | -96.9M | -124M | -111M | -109M | -97.4M | -97.9M |
| EBITDA | -35.8M | -35.8M | -93.9M | -112M | -91.8M | -96.4M | -92.9M | -91.7M |
| Net Income | -35.8M | -36.6M | -95.0M | -132M | -96.0M | -101M | -101M | -90.0M |
| EPS | -0.26 | -6.81 | -1.19 | -0.95 | -0.68 | -0.71 | -0.51 | -0.41 |
| Balance Sheet | ||||||||
| Total Assets | 37.4M | 40.6M | 503M | 391M | 298M | 248M | 246M | 173M |
| Total Liabilities | 1.93M | 4.50M | 26.2M | 32.8M | 26.6M | 32.5M | 25.4M | 12.7M |
| Shareholders' Equity | 35.5M | 36.1M | 477M | 359M | 272M | 215M | 220M | 160M |
| Cash & Short-term Investments | 32.9M | 36.9M | 471M | 351M | 258M | 210M | 163M | 104M |
| Total Debt | - | 1.75M | 8.08M | 17.4M | 15.3M | 12.9M | 4.17M | 2.78M |
| Cash Flow | ||||||||
| Operating Cash Flow | -30.7M | -32.6M | -66.8M | -90.6M | -94.0M | -87.8M | -94.7M | -86.1M |
| Capital Expenditure | 1.24M | 461K | 5.76M | 10.7M | 5.27M | 4.58M | 2.52M | 603K |
| Free Cash Flow | -31.9M | -33.0M | -72.6M | -101M | -99.3M | -92.4M | -97.2M | -86.7M |
| Ratios | ||||||||
| ROE | -101.0% | -101.4% | -19.9% | -36.9% | -35.3% | -46.9% | -46.0% | -56.2% |
| ROA | -95.7% | -90.2% | -18.9% | -33.8% | -32.2% | -40.7% | -41.3% | -52.1% |
| Net Profit Margin | - | - | - | -28,854.5% | -8,868.8% | -3,303.0% | -4,160.1% | -8,295.0% |
| Debt to Equity | - | 0.05x | 0.02x | 0.05x | 0.06x | 0.06x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
QuantumSi Inc dividends
QuantumSi Inc has not paid dividends in the last 7 fiscal years.
Who owns QuantumSi Inc
- Insiders 10.41%
- Institutions 19.26%
- Public & others 70.33%
- Shares outstanding 200M
- Free float 181M
Top funds holding QSI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARK Genomic Revolution ETF | 7.27M | 3.31% | +0.58% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 5.35M | 2.44% | 0.00% | Sep 2026 |
| Amova ARK Pstv Chg Innovt P JPY Acc | 3.04M | 1.38% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 1.32M | 0.60% | -0.19% | Oct 2026 |
| Fidelity Extended Market Index | 858K | 0.39% | -26.90% | Sep 2026 |
| Vanguard Health Care ETF | 504K | 0.23% | +0.11% | Sep 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 461K | 0.21% | 0.00% | Oct 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 436K | 0.20% | +0.03% | Oct 2026 |
| ARK Genomic Revolution ETF A USD Acc | 427K | 0.19% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 328K | 0.15% | -0.05% | Sep 2026 |
| Fidelity Series Total Market Index | 271K | 0.12% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 195K | 0.09% | 0.00% | Oct 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 154K | 0.07% | +0.21% | Oct 2026 |
| Fidelity ZERO Total Market Index | 106K | 0.05% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 84.8K | 0.04% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 83.6K | 0.04% | 0.00% | Sep 2026 |
| Fidelity ZERO Extended Market Index | 81.1K | 0.04% | -20.95% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 58.5K | 0.03% | +7.74% | Jun 2026 |
Top institutions holding QSI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 7.58M | 3.45% | +7.92% | Jun 2026 |
| ARK Investment Management LLC | 7.17M | 3.26% | +4.20% | Jun 2026 |
| BlackRock Inc | 5.23M | 2.38% | -61.05% | Jun 2026 |
| Amova Asset Management Americas, Inc | 3.89M | 1.77% | -11.53% | Jun 2026 |
| Sumitomo Mitsui Trust Group Inc | 3.89M | 1.77% | -11.53% | Jun 2026 |
| Millennium Management LLC | 3.13M | 1.43% | 0.00% | Jun 2026 |
| UBS Group AG | 2.56M | 1.17% | +50.48% | Jun 2026 |
| AQR Capital Management LLC | 2.35M | 1.07% | -1.82% | Jun 2026 |
| Geode Capital Management, LLC | 2.24M | 1.02% | -41.68% | Jun 2026 |
| Jane Street Group LLC | 2.14M | 0.98% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 1.20M | 0.54% | +116.03% | Sep 2026 |
| Susquehanna International Group, LLP | 1.12M | 0.51% | -23.75% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 1.12M | 0.51% | -0.05% | Jun 2026 |
| State Street Corp | 891K | 0.41% | -76.38% | Jun 2026 |
| Fosun International Ltd | 744K | 0.34% | 0.00% | Sep 2026 |
| Vanguard Portfolio Management, LLC | 497K | 0.23% | -67.31% | Jun 2026 |
| The Goldman Sachs Group Inc | 476K | 0.22% | +7.23% | Jun 2026 |
| Northern Trust Corp | 451K | 0.21% | -64.26% | Jun 2026 |
| Amvescap Plc. | 444K | 0.20% | +9.16% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 399K | 0.18% | +938.29% | Jun 2026 |
QuantumSi Inc company profile
- Company name
- QuantumSi Inc
- Ticker
- QSI.US
- Exchange
- USA Stocks
- Listed since
- Jun 10, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 145
- Fiscal year end
- December
- Address
- 29 Business Park Drive, Branford, CT, United States, 06405
- Phone
- 866 688 7374
- Website
- quantum-si.com
About QuantumSi Inc
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer's protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS. It also provides Platinum analysis software, a cloud-based solution that automates data analysis workflows and visualizes the sequencing results. The company was founded in 2013 and is headquartered in Branford, Connecticut.
QuantumSi Inc management
6- Mr. Jeffrey Alan HawkinsPresident, CEO & Director · born 1978
- Dr. Jonathan M. Rothberg Ph.D.Founder & Executive Director · born 1964
- Mr. Jeffry R. Keyes CPACFO & Treasurer · born 1973
- Mr. Ryan MiranovichVice President of Legal
- Ms. Beth PeraltaVice President of Human Resources
- Dr. Christian Lapointe J.D., Ph.D.Corporate Secretary · born 1971